Home
Guide
Picks
High Yield
Dates
Monthly
Screener
Resources
ESG
Retire
Channels
Continue to site >
Trending ETFs
You take care of your investments. We like that.
Upgrade to Premium to access your Watchlist and more.
Or Login to Your Premium Account

VanEck Pharmaceutical ETF

ETF
PPH
Payout Change
Pending
Price as of:
$84.87 -0.32 -0.38%
primary theme
Health Care Sector Equity
PPH (ETF)

VanEck Pharmaceutical ETF

Payout Change
Pending
Price as of:
$84.87 -0.32 -0.38%
primary theme
Health Care Sector Equity
PPH (ETF)

VanEck Pharmaceutical ETF

Payout Change
Pending
Price as of:
$84.87 -0.32 -0.38%
primary theme
Health Care Sector Equity

Name

As of 04/18/2024

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

VanEck Pharmaceutical ETF

PPH | ETF

$84.87

$510 M

1.45%

$1.23

0.36%

Vitals

YTD Return

4.9%

1 yr return

9.9%

3 Yr Avg Return

8.9%

5 Yr Avg Return

10.4%

Net Assets

$510 M

Holdings in Top 10

58.8%

52 WEEK LOW AND HIGH

$85.2
$74.32
$90.89

Expenses

OPERATING FEES

Expense Ratio 0.36%

SALES FEES

Front Load N/A

Deferred Load N/A

TRADING FEES

Turnover 20.00%

Redemption Fee N/A

Min Investment

Standard (Taxable)

N/A

IRA

N/A

Fund Classification

Fund Type

Exchange Traded Fund

Name

As of 04/18/2024

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

VanEck Pharmaceutical ETF

PPH | ETF

$84.87

$510 M

1.45%

$1.23

0.36%

PPH - Profile

Distributions

  • YTD Total Return 4.9%
  • 3 Yr Annualized Total Return 8.9%
  • 5 Yr Annualized Total Return 10.4%
  • Capital Gain Distribution Frequency N/A
  • Net Income Ratio 1.85%
DIVIDENDS
  • Dividend Yield 1.4%
  • Dividend Distribution Frequency None

Fund Details

  • Legal Name
    VanEck Pharmaceutical ETF
  • Fund Family Name
    VANECKFUND
  • Inception Date
    Dec 20, 2011
  • Shares Outstanding
    6088138
  • Share Class
    N/A
  • Currency
    USD
  • Domiciled Country
    US
  • Manager
    Peter Liao

Fund Description

The Fund normally invests at least 80% of its total assets in securities that comprise the Fund’s benchmark index. The Pharmaceutical Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. To be initially eligible for the Pharmaceutical Index, companies must generate at least 50% of their revenues from pharmaceuticals. Pharmaceuticals include companies engaged primarily in research (including research contractors) and development as well as production, marketing and sales of pharmaceuticals (excluding pharmacies). Of the largest 50 stocks in the pharmaceutical industry by full market capitalization, the top 25 by free-float market capitalization (i.e., includes only shares that are readily available for trading in the market) and three month average daily trading volume are included in the Pharmaceutical Index. As of December 31, 2023, the Pharmaceutical Index included 25 securities of companies with a market
capitalization range of between approximately $2.6 billion and $553.3 billion and a weighted average market capitalization of $190.8 billion. These amounts are subject to change. The Fund’s 80% investment policy is non-fundamental and may be changed without shareholder approval upon 60 days’ prior written notice to shareholders.
The Fund, using a “passive” or indexing investment approach, attempts to approximate the investment performance of the Pharmaceutical Index by investing in a portfolio of securities that generally replicates the Pharmaceutical Index. Unlike many investment companies that try to “beat” the performance of a benchmark index, the Fund does not try to “beat” the Pharmaceutical Index and does not seek temporary defensive positions that are inconsistent with its investment objective of seeking to replicate the Pharmaceutical Index.
The Fund is classified as a non-diversified fund under the Investment Company Act of 1940 and, therefore, may invest a greater percentage of its assets in a particular issuer. The Fund may concentrate its investments in a particular industry or group of industries to the extent that the Pharmaceutical Index concentrates in an industry or group of industries. As of September 30, 2023, the pharmaceutical industry and the health care sector represented a significant portion of the Fund.
Read More

PPH - Performance

Return Ranking - Trailing

Period PPH Return Category Return Low Category Return High Rank in Category (%)
YTD 4.9% -28.1% 11.7% 5.52%
1 Yr 9.9% -28.8% 21.4% 16.56%
3 Yr 8.9%* -35.6% 11.4% 1.28%
5 Yr 10.4%* -7.0% 14.7% 24.82%
10 Yr 6.0%* 0.2% 13.6% 84.11%

* Annualized

Return Ranking - Calendar

Period PPH Return Category Return Low Category Return High Rank in Category (%)
2023 4.7% -12.6% 19.0% 25.77%
2022 1.0% -53.9% 3.2% 1.92%
2021 15.8% -39.6% 24.2% 6.41%
2020 3.6% -13.6% 178.2% 88.74%
2019 17.1% 3.8% 63.8% 76.30%

Total Return Ranking - Trailing

Period PPH Return Category Return Low Category Return High Rank in Category (%)
YTD 4.9% -28.1% 11.7% 5.52%
1 Yr 9.9% -28.8% 21.4% 16.56%
3 Yr 8.9%* -35.6% 11.4% 1.28%
5 Yr 10.4%* -7.0% 14.7% 24.82%
10 Yr 6.0%* 0.2% 13.6% 84.11%

* Annualized

Total Return Ranking - Calendar

Period PPH Return Category Return Low Category Return High Rank in Category (%)
2023 6.9% -12.6% 19.0% 27.61%
2022 2.6% -53.9% 3.7% 1.28%
2021 17.8% -33.9% 26.0% 18.59%
2020 5.5% -0.7% 180.6% 96.03%
2019 19.4% 4.6% 63.8% 88.15%

PPH - Holdings

Concentration Analysis

PPH Category Low Category High PPH % Rank
Net Assets 510 M 7.41 M 47.2 B 56.44%
Number of Holdings 26 23 413 99.39%
Net Assets in Top 10 265 M 2.19 M 20.5 B 55.21%
Weighting of Top 10 58.79% 18.1% 77.0% 11.66%

Top 10 Holdings

  1. Eli Lilly Co 9.14%
  2. Novo Nordisk A/S 7.88%
  3. Johnson Johnson 6.68%
  4. AbbVie Inc 5.36%
  5. Merck Co Inc 5.35%
  6. Novartis AG 5.10%
  7. AstraZeneca PLC 5.10%
  8. Pfizer Inc 4.81%
  9. Zoetis Inc 4.70%
  10. Sanofi SA 4.68%

Asset Allocation

Weighting Return Low Return High PPH % Rank
Stocks 		100.15% 87.17% 106.13% 1.84%
Cash 		0.69% 0.00% 32.99% 74.85%
Preferred Stocks 		0.00% 0.00% 7.86% 36.81%
Other 		0.00% -22.99% 17.73% 38.04%
Convertible Bonds 		0.00% 0.00% 0.37% 13.92%
Bonds 		0.00% 0.00% 12.39% 19.63%

Stock Sector Breakdown

Weighting Return Low Return High PPH % Rank
Healthcare 		100.00% 59.26% 100.00% 5.06%
Utilities 		0.00% 0.00% 0.00% 6.96%
Technology 		0.00% 0.00% 22.69% 13.29%
Real Estate 		0.00% 0.00% 5.89% 10.76%
Industrials 		0.00% 0.00% 7.02% 12.66%
Financial Services 		0.00% 0.00% 1.60% 32.28%
Energy 		0.00% 0.00% 0.00% 6.96%
Communication Services 		0.00% 0.00% 9.11% 10.13%
Consumer Defense 		0.00% 0.00% 25.73% 18.99%
Consumer Cyclical 		0.00% 0.00% 1.92% 12.66%
Basic Materials 		0.00% 0.00% 7.16% 38.61%

Stock Geographic Breakdown

Weighting Return Low Return High PPH % Rank
US 		100.15% 66.21% 104.41% 1.23%
Non US 		0.00% 0.00% 28.58% 58.28%

PPH - Expenses

Operational Fees

PPH Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 0.36% 0.08% 4.28% 92.64%
Management Fee 0.35% 0.03% 1.25% 4.91%
12b-1 Fee N/A 0.00% 1.00% N/A
Administrative Fee N/A 0.03% 0.25% N/A

Sales Fees

PPH Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 3.50% 5.75% N/A
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

PPH Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 1.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

PPH Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 20.00% 0.00% 238.00% 18.84%

PPH - Distributions

Dividend Yield Analysis

PPH Category Low Category High PPH % Rank
Dividend Yield 1.45% 0.00% 6.36% 16.56%

Dividend Distribution Analysis

PPH Category Low Category High Category Mod
Dividend Distribution Frequency None Annual Quarterly Annual

Net Income Ratio Analysis

PPH Category Low Category High PPH % Rank
Net Income Ratio 1.85% -2.54% 1.85% 0.64%

Capital Gain Distribution Analysis

PPH Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Semi-Annually Annually

Distributions History

View More +

PPH - Fund Manager Analysis

Managers

Peter Liao

Start Date

Tenure

Tenure Rank

Dec 20, 2011

10.45

10.5%

Mr. Liao has been employed by Van Eck Associates Corporation as an analyst since the summer of 2004 and has been a portfolio manager since 2006. Mr. Liao graduated from New York University in 2004 with a Bachelor of Arts in Economics and Mathematics. He is a CFA charterholder.

Guo Hua (Jason) Jin

Start Date

Tenure

Tenure Rank

Feb 01, 2018

4.33

4.3%

Guo Hua (Jason) Jin has been employed by Van Eck Associates Corporation as an analyst since January 2007 and has been a portfolio manager since 2018. Mr. Jin graduated from the State University of New York at Buffalo in 2004 with a Bachelor of Science degree in Business Administration with a concentration in Financial Analysis.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.02 24.72 7.84 0.25

Advertisement

×

Wait! Rates are rising, is your portfolio ready?

×